Director John Montalbano adds 20,000 AbCellera (ABCL) shares in open trade

Rhea-AI Filing Summary

AbCellera Biologics Inc. director John S. Montalbano reported buying additional company stock. On May 14, 2026, he made an open-market purchase of 20,000 Common Shares at $4.77 per share. After this transaction, he holds 241,000 Common Shares directly and 5,000 Common Shares indirectly through his spouse.

Insider Trade Summary

Net Buyer: 20,000 shares ($95,400)

Net Buy 2 txns

Insider Montalbano John S.

Role null

Bought 20,000 shs ($95K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	20,000	$4.77	$95K
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 241,000 shares (Direct, null); Common Shares — 5,000 shares (Indirect, By Spouse)

Footnotes (1)

Key Figures

Shares purchased: 20,000 shares Purchase price: $4.77 per share Direct holdings after trade: 241,000 shares +1 more

4 metrics

Shares purchased 20,000 shares Open-market purchase of Common Shares on May 14, 2026

Purchase price $4.77 per share Price paid for the 20,000 Common Shares

Direct holdings after trade 241,000 shares Common Shares held directly following the purchase

Indirect holdings by spouse 5,000 shares Common Shares reported as held indirectly by spouse

Key Terms

open-market purchase, Common Shares, indirect ownership, Form 4

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Shares financial

"security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

indirect ownership financial

"ownership_type: "indirect" and nature_of_ownership: "By Spouse""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Montalbano John S.

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/14/2026		P	V	20,000	A	$4.77	241,000	D
Common Shares								5,000	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Tryn Stimart, attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AbCellera (ABCL) director John S. Montalbano report?

Director John S. Montalbano reported buying AbCellera Common Shares. He executed an open-market purchase, increasing his direct ownership stake in the company, as disclosed in a Form 4 insider trading report filed with regulators.

How many AbCellera (ABCL) shares did John S. Montalbano purchase and at what price?

He purchased 20,000 AbCellera Common Shares at $4.77 per share. This open-market transaction increased his direct holdings and reflects an additional personal capital commitment at that specific trading price.

What are John S. Montalbano’s total direct AbCellera (ABCL) holdings after the Form 4 transaction?

After the reported transaction, he directly holds 241,000 AbCellera Common Shares. This figure represents his direct ownership position immediately following the open-market purchase disclosed in the Form 4 filing.

Does John S. Montalbano report any indirect ownership of AbCellera (ABCL) shares?

Yes. The filing shows 5,000 Common Shares held indirectly “By Spouse”. These shares are reported as indirect ownership, separate from his 241,000 directly held AbCellera Common Shares after the transaction.

Was the AbCellera (ABCL) insider trade an open-market purchase?

Yes. The Form 4 describes the transaction as an open-market purchase of Common Shares. This means the director acquired shares at prevailing market prices rather than through options, grants, or other non-market mechanisms.